WuXi Biologics (Cayman) Inc.
WXIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $18,675 | $17,034 | $15,269 | $10,290 |
| % Growth | 9.6% | 11.6% | 48.4% | – |
| Cost of Goods Sold | $11,025 | $10,206 | $8,545 | $5,461 |
| Gross Profit | $7,651 | $6,828 | $6,724 | $4,829 |
| % Margin | 41% | 40.1% | 44% | 46.9% |
| R&D Expenses | $766 | $793 | $683 | $502 |
| G&A Expenses | $1,674 | $1,495 | $1,270 | $876 |
| SG&A Expenses | $2,147 | $1,789 | $1,433 | $1,001 |
| Sales & Mktg Exp. | $474 | $294 | $163 | $125 |
| Other Operating Expenses | -$237 | -$204 | $267 | $139 |
| Operating Expenses | $2,677 | $2,378 | $2,382 | $1,641 |
| Operating Income | $4,974 | $4,450 | $4,342 | $3,188 |
| % Margin | 26.6% | 26.1% | 28.4% | 31% |
| Other Income/Exp. Net | -$139 | -$276 | $1,016 | $805 |
| Pre-Tax Income | $4,834 | $4,174 | $5,358 | $3,993 |
| Tax Expense | $889 | $603 | $808 | $485 |
| Net Income | $3,356 | $3,400 | $4,420 | $3,388 |
| % Margin | 18% | 20% | 29% | 32.9% |
| EPS | 0.82 | 0.81 | 1.06 | 0.81 |
| % Growth | 1.2% | -23.6% | 30.9% | – |
| EPS Diluted | 0.78 | 0.77 | 1.01 | 0.77 |
| Weighted Avg Shares Out | 4,082 | 4,164 | 4,173 | 4,401 |
| Weighted Avg Shares Out Dil | 4,227 | 4,349 | 4,376 | 4,422 |
| Supplemental Information | – | – | – | – |
| Interest Income | $350 | $219 | $107 | $58 |
| Interest Expense | $158 | $158 | $64 | $39 |
| Depreciation & Amortization | $1,437 | $1,169 | $801 | $482 |
| EBITDA | $6,429 | $5,502 | $6,223 | $4,514 |
| % Margin | 34.4% | 32.3% | 40.8% | 43.9% |